Data on the safety and effectiveness of the vaccine against COVID-19 Johnson & Johnson, recently published in the New England Journal of Medicine, showed that the second dose of the injection provides protection of up to 82%.
Vials and syringes with the vaccine against COVID-19 Johnson and Johnson Jansen are shown for photography at the Culver City Fire Department Vaccination Clinic on August 5, 2021 in California. Photo: Patrick T. Fallon / AFP
CAPE TOWN – Sisonke researchers have emphasized that the J&J vaccine against COVID-19 is equally effective against Omicron subvariants.
Subvariants stimulate the rebirth of infections.
The Sisonke vaccination program was launched in February 2021 to make coronavirus vaccines available to healthcare professionals.
Data on the safety and efficacy of the vaccine against COVID-19 Johnson & Johnson, recently published in New England Medical Journalfound that the second dose of impact provided protection of up to 82%.
“This is very good news because it means that our vaccines are effective in South Africa against these care options, and it also supports the fact that people need to confidently go out for vaccination and get vaccinated,” said one of the study’s lead researchers. . , explained Professor Linda-Gail Becker.
Becker said the study compared the effectiveness of two doses of the COVID-19 Johnson & Johnson vaccine with two doses of Pfizer injections.
“During the time Omnicron was circulating in South Africa, we found that the two vaccines were comparable, especially in the early stages of Omnicron against hospitalization with COVID-19, high care or resuscitation, and this was seen for both vaccines,” she said. she. .